The topic Focal Non-Epidermolytic Palmoplantar Keratoderma with Carcinoma of the Esophagus you are seeking is a synonym, or alternative name, or is closely related to the medical condition Howel-Evans Syndrome.

Quick Summary:

• Howel-Evans Syndrome is an extremely rare form of hereditary focal palmoplantar keratoderma that is transmitted in an autosomal dominant manner. The condition manifests during early childhood and is associated with cancer of the esophagus (food-pipe). It is also known as Tylosis with Esophageal Cancer (or simply Tylosis)
• Hereditary focal palmoplantar keratoderma is a type of palmoplantar keratoderma (PPK) caused by genetic mutations. PPK is a benign skin condition, wherein there is thickening of skin (keratoderma) of the palms and/or soles. PPK is considered to be a pattern of skin findings and not a condition in itself. The abnormal skin thickening can be focal (localized), widespread (diffused), or punctate type (appearing as tiny bumps)
• There are two types of Howel-Evans Syndrome (Tylosis):
  • Type A Tylosis: It has a late-onset and is mostly associated with esophageal cancer
  • Type B Tylosis: It has an early onset and has usually a benign course (association with esophageal cancer is less often seen)
• A diagnosis of Howel-Evans Syndrome can be made by clinical (skin) exam and various other diagnostic tools including dermoscopy and wood’s lamp examination. The treatment for skin symptoms involves the use of moisturizers, topical creams, and skin softeners; the associated esophageal cancer may be managed using surgery, chemotherapy, and radiation therapy
• The prognosis of Howel-Evans Syndrome is determined on a case-by-case basis. In case of formation of esophageal cancer, the overall prognosis depends on several factors, including on the stage of the cancer

 Please find comprehensive information on Howel-Evans Syndrome regarding definition, distribution, risk factors, causes, signs & symptoms, diagnosis, complications, treatment, prevention, prognosis, and additional useful information HERE.